- Home
- NXGL vs RDHL Comparison
NXGL vs RDHL Comparison
Compare NXGL & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXGL | RDHL |
|---|---|---|
| Founded | 1997 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 3.3M |
| IPO Year | 2019 | 2012 |
Fundamental Metrics
Financial Performance| Metric | NXGL | RDHL |
|---|---|---|
| Price | $0.18 | $0.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | 138.0K | ★ 2.5M |
| Earning Date | 05-11-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,421,000.00 | N/A |
| Revenue This Year | $50.77 | $381.91 |
| Revenue Next Year | $46.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 31.46 | N/A |
| 52 Week Low | $0.24 | $0.52 |
| 52 Week High | $2.89 | $2.79 |
Technical Indicators
Market Signals| Indicator | NXGL | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 25.63 | 34.51 |
| Support Level | N/A | N/A |
| Resistance Level | $0.38 | $1.07 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 16.72 | 0.00 |
Price Performance
Historical ComparisonAbout NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.